Scientific Evidence to Optimise Value
Our mission is to provide the highest level of scientific evidence to optimise the real world value and health impact of medicines & health technologies.
LA-SER has offices across Europe and in North America and teams acting in North Africa, providing significant global reach. Our Headquarters are based in London.
History & Experience
Over the last two decades, the global healthcare industry has evolved, leading to a growing demand from regulatory agencies, HTA agencies, and payers to actively demonstrate the real-world value and safety of medicines, devices, and other health products. The LA-SER Group has emerged and developed along with this changing healthcare landscape, growing to meet the needs of clients in the pharmaceutical, medical device, and biotechnology industries.
Building on the experience of the initial, near-academic company The Centre for Risk Research Inc., founded in 1992 in Montreal (Canada) by Lucien Abenhaim, the LA-SER team was created in 2004 in Paris and established its headquarters in London (UK) in 2009. Since that time, LA-SER has engaged in a series of mergers and acquisitions in order to expand the organization’s capabilities in health outcomes research, analytics, and strategy consulting. Currently, the LA-SER Group’s team is composed of over 200 highly-trained scientific staff with experience in a host of key disciplines including epidemiology, pharmacoepidemiology, clinical pharmacology, public health, biostatistics, health economics, quantitative social research, and others. Our research is presented at industry conferences and academic symposia, published in peer-reviewed journals, and cited by leading health technology assessment bodies.
With eight offices spanning three continents, the LA-SER Group is well-positioned to provide strategic consulting and scientific research services to the dedicated and highly motivated professionals in the global healthcare industry.
REAL WORLD RESEARCH
Assessment of the relative effectiveness of products in the real life through the design and conduct of advanced pharmacoepidemiological studies, using a variety of data sources: clinical data, eMR, eHCD
Risk management and response to crisis through the conduct of sophisticated pharmacoepidemiology studies at the request of health authorities such as EMA or FDA
Real world Impact studies conducted for Managed entry schemes, risk sharing agreement, drug positioning and population targeting, drug and health care use utilization studies
ANALYTICS & HEOR
Decision analytics through advanced modeling, Bayesian-based simulations, epidemiological models, bridging studies models from trials to real life
Health Economics studies of costs, cost-effectiveness analysis using Markov and DES models, budget impact models
Market Access analysis through payers’ research, pricing consultancy, landscape characterization,
HTA strategies through the conception and writing of global value dossiers, submissions to agencies in several countries,
Multi-Criteria Decision Analysis to support drug development, market access strategies and HTA submission
Outcomes research and target population assessment through the evaluation of burden of disease, drug utilization studies, surveys of patients and physicians
Patients reported outcomes measures (PROMs) and Utility assessment, also offering of alternative solutions based on response theory and computer-assisted technology
The Arcana Institute is also an expert group in Evidence synthesis through Systematic reviews, mixed-treatment comparisons, network analysis. It produces the ‘Market Access Analyser and ‘Predeciser for CEE countries.